Millipore Sigma Vibrant Logo

524403 Pravastatin, Sodium Salt - CAS 81131-70-6 - Calbiochem

A water-soluble, competitive 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor that potently blocks in vivo cholesterol synthesis (Ki = ~1 nM).

MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

Synonyms: (βR,δR,1S,2S,6S,8S,8aR)-1,2,6,7,8,8a-Hexahydro-β,δ,6-trihydroxy-2-methyl-8[(2S)-2-methyl-1-oxobutoxyl]-1-naphthaleneheptanoic Acid Na, 3β-Hydroxycompactin, Na

Primary Target: AMG-CoA reductase
View Products on Sigmaaldrich.com
524403
가격 및 재고 조회

개요

Replacement Information

주요 사양표

CAS #Empirical Formula
81131-70-6C₂₃H₃₅O₇.Na

가격 및 재고여부

카탈로그 번호 재고 정보패킹 포장 단위 가격(VAT 별도) 수량
524403-25MGCN
재고 정보 검색...
—
현재 재고 없음 현재 재고 없음
예상 출고 가능일 
단종품
제한된 수량 가능
재고여부 확인
    Remaining: will advise
      Remaining: will advise
      추천사항
      고객 서비스로 문의
      Contact Customer Service

      		 Plastic Bag(s) 25 mg
      가격 검색...
      가격을 검색할 수 없습니다
      Minimum Quantity needs to be mulitiple of
      Maximum Quantity is
      가격 문의 추가 정보
      ()이 할인됨
       
      —
      가격 문의
      		 —
      Description
      OverviewA water-soluble, competitive 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor that potently blocks in vivo cholesterol synthesis (Ki = ~1 nM). Offers cardioprotection. Also acts as an immunomodulator and an inhibitor of ras p21 isoprenylation.
      Catalogue Number524403
      Brand Family Calbiochem®
      Synonyms(βR,δR,1S,2S,6S,8S,8aR)-1,2,6,7,8,8a-Hexahydro-β,δ,6-trihydroxy-2-methyl-8[(2S)-2-methyl-1-oxobutoxyl]-1-naphthaleneheptanoic Acid Na, 3β-Hydroxycompactin, Na
      References
      ReferencesKwak, B., et al. 2000. Natl. Med. 6, 1399.
      Hamelin, B.A., and Turgeon, J., 1998. Trends Pharmacol. Sci. 19, 26.
      Narisawa, T., et al. 1996. Jpn. J. Cancer Res. 87, 798.
      Cohen, L.H., et al. 1993. Biochem. Pharmacol. 45, 2203.
      Koga, T., et al. 1990. Biochim. Biophys. Acta. 1045, 115.
      Yoshino, G., et al. 1986. Diabetes Res. Clin. Pract. 2, 179
      Product Information
      CAS number81131-70-6
      ATP CompetitiveN
      FormWhite crystalline solid
      Hill FormulaC₂₃H₃₅O₇.Na
      Chemical formulaC₂₃H₃₅O₇.Na
      Hygroscopic Hygroscopic
      ReversibleN
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary TargetAMG-CoA reductase
      Primary Target K<sub>i</sub>~1 nM inhibiting 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and blocking in vivo cholesterol synthesis
      Purity≥98% by HPLC
      Physicochemical Information
      Cell permeableN
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      RTECSQJ7185000
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Environmental Hazard
      Hazardous Materials Attention: Due to the nature of the Hazardous Materials in this shipment, additional shipping charges may be applied to your order. Certain sizes may be exempt from the additional hazardous materials shipping charges. Please contact your local sales office for more information regarding these charges.
      Storage +2°C to +8°C
      Hygroscopic Hygroscopic
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      카탈로그 번호 GTIN
      524403-25MGCN 04055977270983

      Documentation

      Pravastatin, Sodium Salt - CAS 81131-70-6 - Calbiochem MSDS

      타이틀

      물질안전보건자료(MSDS) 

      Pravastatin, Sodium Salt - CAS 81131-70-6 - Calbiochem Certificates of Analysis

      TitleLot Number
      524403

      References

      참고문헌 보기
      Kwak, B., et al. 2000. Natl. Med. 6, 1399.
      Hamelin, B.A., and Turgeon, J., 1998. Trends Pharmacol. Sci. 19, 26.
      Narisawa, T., et al. 1996. Jpn. J. Cancer Res. 87, 798.
      Cohen, L.H., et al. 1993. Biochem. Pharmacol. 45, 2203.
      Koga, T., et al. 1990. Biochim. Biophys. Acta. 1045, 115.
      Yoshino, G., et al. 1986. Diabetes Res. Clin. Pract. 2, 179
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision16-May-2008 RFH
      Synonyms(βR,δR,1S,2S,6S,8S,8aR)-1,2,6,7,8,8a-Hexahydro-β,δ,6-trihydroxy-2-methyl-8[(2S)-2-methyl-1-oxobutoxyl]-1-naphthaleneheptanoic Acid Na, 3β-Hydroxycompactin, Na
      DescriptionA water-soluble, competitive 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor that blocks in vivo cholesterol synthesis (Ki ~1 nM). Also acts as an immunomodulator and an inhibitor of ras p21 isoprenylation.
      FormWhite crystalline solid
      Intert gas (Yes/No) Packaged under inert gas
      CAS number81131-70-6
      RTECSQJ7185000
      Chemical formulaC₂₃H₃₅O₇.Na
      Structure formulaStructure formula
      Purity≥98% by HPLC
      SolubilityH₂O (100 mg/ml)
      Storage +2°C to +8°C
      Hygroscopic
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Environmental Hazard
      Merck USA index14, 7714
      ReferencesKwak, B., et al. 2000. Natl. Med. 6, 1399.
      Hamelin, B.A., and Turgeon, J., 1998. Trends Pharmacol. Sci. 19, 26.
      Narisawa, T., et al. 1996. Jpn. J. Cancer Res. 87, 798.
      Cohen, L.H., et al. 1993. Biochem. Pharmacol. 45, 2203.
      Koga, T., et al. 1990. Biochim. Biophys. Acta. 1045, 115.
      Yoshino, G., et al. 1986. Diabetes Res. Clin. Pract. 2, 179